Developer docs
API playgroundTry for free, no card

Search company profiles

Kannalife

Full company profile

uuid0003h37

Namestring
Kannalife
Legal namestring
Kannalife Sciences, Inc.
Websiteurl
kannalife.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

Kannalife Sciences, Inc. is a Doylestown, Pennsylvania-based biopharmaceutical company founded in 2010 by Dean Petkanas and Thoma Kikis, operating as a wholly owned subsidiary of Neuropathix, Inc. (publicly listed on OTCQB as KLFE). The company develops a proprietary pipeline of synthetic, CBD-inspired New Chemical Entities (NCEs) for neurological and inflammatory indications. Its lead candidate, KLS-13019, is a first-in-class synthetic CBD analogue positioned for chemotherapy-induced peripheral neuropathy, hepatic encephalopathy, Parkinson's disease, and opioid use disorder, claiming up to 200X potency, 10X bioavailability, and 5X safety advantages versus CBD via a dual GPR55 antagonism and mitochondrial NCX-1 mechanism. Additional pipeline assets include KLS-13023 (oral gelcap for hepatic encephalopathy), KLS-13022 (topical OTC formulation), and the Atopidine™ (LEA) consumer skincare product.

The company's technology platform sits on an exclusive license to U.S. Patent #6630507 (NIH Office of Technology Transfer) covering cannabinoids as antioxidants and neuroprotectants, supplemented by composition-of-matter and method-of-treatment patents granted in the US, Japan, Russia, China, and EU with applications pending in additional jurisdictions. Scientific operations are anchored by research collaborations with Temple University's Lewis Katz School of Medicine, University of Würzburg, and Atuka, Inc., and a Scientific Advisory Board drawn from Johnson & Johnson, Novartis, Novo Nordisk, and Purdue Pharma alumni.

Kannalife is pre-commercial and currently funds operations through non-dilutive grants (NIH NIDA, NIH NINDS HEAL Initiative, Michael J. Fox Foundation totaling ~$4.76M), a forward capital commitment from life-sciences VC Prevail Partners, and OTCQB market access. The company has 1-10 employees and an IND filing for KLS-13019 is anticipated in 2026. The go-to-market strategy targets pharmaceutical partnership and licensing for the drug assets and OTC consumer distribution for Atopidine™, with no commercial products or pricing in market today.

Short descriptiontext

Kannalife Sciences is a Doylestown, Pennsylvania-based biopharmaceutical company developing synthetic CBD-inspired new chemical entities led by KLS-13019, targeting chemotherapy-induced peripheral neuropathy, Parkinson's disease, hepatic encephalopathy, and other neurological disorders, with additional OTC skincare products Atopidine™ in its pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDoylestown, United States
HQ citystring
Doylestown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabinoid therapeutics, biopharmaceutical research, neuropathic pain treatment, CBD-inspired molecules, drug discovery
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Grant Funding
TypeLicensing Royalties
Description

Pre-commercial revenue derived entirely from NIH, NINDS, HEAL Initiative, and Michael J. Fox Foundation grants supporting preclinical research and IND-enabling studies.

kannalife.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Atopidine™
Description

A proprietary, investigational, novel monotherapeutic product for potential treatment of skin care, anti-inflammatory, antioxidant, and personal care needs. A CBD-inspired molecule shown to outperform CBD in preventing inflammatory responses relevant to UVB-radiation.

kannalife.com
Core offering1 text field

Kannalife Sciences is a biopharmaceutical company focused on the research and development of a pipeline of synthetic CBD-inspired New Chemical Entities (NCEs) targeting neuroinflammation and mitochondrial dysfunction. Its lead drug candidate KLS-13019 is being advanced for chemotherapy-induced peripheral neuropathy (CIPN), Parkinson's disease, opioid use disorder, and hepatic encephalopathy, while Atopidine™ is being prepared as an OTC topical skin care product.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • KLS-13019 is up to 200X more potent than CBD
+6 more records
Product overview1 text field

Kannalife Sciences is a biopharmaceutical company developing a pipeline of synthetic CBD-like therapeutic molecules. The core portfolio consists of KLS-13019 as the lead drug candidate for multiple indications including CIPN, Parkinson's disease, and opioid use disorder; KLS-13023 as an oral formulation for Hepatic Encephalopathy; and KLS-13022 as a topical cream for skin disorders. Additionally, Atopidine™ represents a consumer-facing topical product for anti-inflammatory skin care applications.

Product and service4 records
1KLS-13019
CategoryDrug Candidate
Description

First-in-class synthetic CBD-like New Chemical Entity (NCE) and lead drug candidate targeting chemotherapy-induced peripheral neuropathy (CIPN), Parkinson's disease, opioid use disorder, and refractory colon cancer. Features a dual mechanism of action: GPR55 antagonism (anti-inflammatory) and mitochondrial NCX-1 regulation (neuroprotection). Demonstrated 67% oral bioavailability and blood-brain barrier penetration.

2KLS-13023
CategoryDrug Candidate
Description

Oral gelcap therapeutic candidate in the KLS family designed to target neurotoxicity caused by ammonia and ethanol in the brain for potential treatment of Hepatic Encephalopathy (HE). Shown to be 50x more potent than CBD in protecting hippocampal neurons from oxidative stress associated with liver failure.

3KLS-13022
CategoryDrug Candidate
Description

Topical cream formulation in early discovery/optimization stage targeting OTC skin disorders including pain, itch, and burn indications, with a target to be OTC ready by late 2026.

4Atopidine™ (LEA)
CategoryConsumer Product
Description

Proprietary, investigational topical formulation (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine / LEA) intended for skin care and anti-inflammatory consumer applications. Shown in pre-clinical testing to have protective and anti-inflammatory properties, outperforming CBD in preventing inflammatory responses relevant to UVB-radiation including TNF-alpha, IL-1beta and IL-6 release from human epidermal cells. Planned for OTC launch.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Universitätsklinikum Würzburg (University of Würzburg)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-06-25
Description

Research partnership with Prof. Dr. Med. Chi Wang Ip for Parkinson's disease research program. Collaboration as part of MJFF-funded preclinical studies on KLS-13019 targeting neuroinflammation and mitochondrial dysfunction.

kannalife.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-06-25
Description

Research partnership with Tom H. Johnston, PhD and James P. Koprich, MA, PhD for Parkinson's disease research program. Collaboration on preclinical efficacy studies of KLS-13019 for PD treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-11
Description

Collaborative research with Dr. Sara Jane Ward's laboratory for KLS-13019 studies in animal models of chemotherapy-induced peripheral neuropathy (CIPN). Research performed under NIH-NIDA Phase 1 grant (1R41DA044898-01) to assess KLS-13019 as non-opioid treatment for neuropathic pain.

Strategic tierStrategicTypeTechnology or Integration
Description

Partnership for Chemistry, Manufacturing, and Controls (CMC) services. Partners in proprietary, scaled-up CMC for KLS-13019 drug substance and drug product manufacturing for IND-enabling studies and clinical trials.

Strategic tierSupportingTypeOthers
Description

Nonprofit life sciences incubator-accelerator providing state-of-the-art laboratory and office space to Kannalife. Located near Doylestown in the Philadelphia-New Jersey pharma belt. Supports nearly 80 member companies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major biopharma with historic leadership in neuropathic pain and CIPN therapeutics. Relevant as the archetypal acquirer/partner for late-stage cannabinoid or non-opioid pain assets.

TypeDirect peer
Description

CNS-focused biopharmaceutical company developing therapeutics for migraine, depression, and CNS disorders. Highly relevant non-opioid neuropathic pain and CNS comparator with similar small-cap, R&D-intensive profile.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing cannabinoid-derived and related small molecules for inflammatory and fibrotic diseases. Closely comparable in stage, therapeutic philosophy (synthetic cannabinoid-inspired NCEs), and CNS/inflammation pipeline focus.

4Tetra Bio-Pharma
TypeDirect peer
Description

Canadian cannabinoid-based drug development company focused on pain, inflammation, and oncology-supportive care. Overlaps with Kannalife on cannabinoid-derived molecules for neuropathic pain and CIPN-like indications.

5Tilray Brands
TypeBroad incumbent
Description

Large, publicly traded cannabis company with pharmaceutical division pursuing cannabinoid-derived therapeutics. Comparable in cannabinoid therapeutic pipeline but operates at significantly larger scale and broader commercial footprint.

TypeDirect peer
Description

Cannabinoid-focused biotech with overlapping board and investor connections to Kannalife. Pursues cannabinoid therapeutics in pain and CNS indications, making it a closely comparable small-cap peer.

TypeBroad incumbent
Description

Acquired GW Pharmaceuticals, the global leader in approved cannabinoid therapeutics (Sativex, Epidiolex), making it the most directly comparable large pharma counterpart in cannabinoid CNS drug development. Competes for the same physician and patient pools that Kannalife's KLS-13019 targets in neuropathic pain and neurology.

TypeDirect peer
Description

Clinical-stage company developing cannabinoid-based therapeutics for diseases with high unmet medical need. Comparable in being a small-cap, R&D-focused cannabinoid pharma pursuing CNS and rare-disease indications.

TypeOthers
TypeEmerging player
Description

Clinical-stage biotherapeutics company developing CNS and inflammation programs. Comparable as a small, R&D-heavy platform developing CNS-focused novel mechanisms toward partnership with larger pharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kannalife

Biopharmaceuticalskannalife.com

Kannalife Sciences is a Doylestown, Pennsylvania-based biopharmaceutical company developing synthetic CBD-inspired new chemical entities led by KLS-13019, targeting chemotherapy-induced peripheral neuropathy, Parkinson's disease, hepatic encephalopathy, and other neurological disorders, with additional OTC skincare products Atopidine™ in its pipeline.

What Kannalife does

Kannalife Sciences, Inc. is a Doylestown, Pennsylvania-based biopharmaceutical company founded in 2010 by Dean Petkanas and Thoma Kikis, operating as a wholly owned subsidiary of Neuropathix, Inc. (publicly listed on OTCQB as KLFE). The company develops a proprietary pipeline of synthetic, CBD-inspired New Chemical Entities (NCEs) for neurological and inflammatory indications. Its lead candidate, KLS-13019, is a first-in-class synthetic CBD analogue positioned for chemotherapy-induced peripheral neuropathy, hepatic encephalopathy, Parkinson's disease, and opioid use disorder, claiming up to 200X potency, 10X bioavailability, and 5X safety advantages versus CBD via a dual GPR55 antagonism and mitochondrial NCX-1 mechanism. Additional pipeline assets include KLS-13023 (oral gelcap for hepatic encephalopathy), KLS-13022 (topical OTC formulation), and the Atopidine™ (LEA) consumer skincare product.

The company's technology platform sits on an exclusive license to U.S. Patent #6630507 (NIH Office of Technology Transfer) covering cannabinoids as antioxidants and neuroprotectants, supplemented by composition-of-matter and method-of-treatment patents granted in the US, Japan, Russia, China, and EU with applications pending in additional jurisdictions. Scientific operations are anchored by research collaborations with Temple University's Lewis Katz School of Medicine, University of Würzburg, and Atuka, Inc., and a Scientific Advisory Board drawn from Johnson & Johnson, Novartis, Novo Nordisk, and Purdue Pharma alumni.

Kannalife is pre-commercial and currently funds operations through non-dilutive grants (NIH NIDA, NIH NINDS HEAL Initiative, Michael J. Fox Foundation totaling ~$4.76M), a forward capital commitment from life-sciences VC Prevail Partners, and OTCQB market access. The company has 1-10 employees and an IND filing for KLS-13019 is anticipated in 2026. The go-to-market strategy targets pharmaceutical partnership and licensing for the drug assets and OTC consumer distribution for Atopidine™, with no commercial products or pricing in market today.

Kannalife firmographics

Firmographics
Name
Kannalife
Legal name
Kannalife Sciences, Inc.
Website
https://kannalife.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
Kannalife Sciences is a Doylestown, Pennsylvania-based biopharmaceutical company developing synthetic CBD-inspired new chemical entities led by KLS-13019, targeting chemotherapy-induced peripheral neuropathy, Parkinson's disease, hepatic encephalopathy, and other neurological disorders, with additional OTC skincare products Atopidine™ in its pipeline.
Ownership category
akta.pro rank

Kannalife industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Cannabinoid therapeutics
  • Biopharmaceutical research
  • Neuropathic pain treatment
  • CBD-inspired molecules
  • Drug discovery

Where Kannalife is headquartered

Location

Headquarters

HQ city
Doylestown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kannalife business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Grant Funding: Pre-commercial revenue derived entirely from NIH, NINDS, HEAL Initiative, and Michael J. Fox Foundation grants supporting preclinical research and IND-enabling studies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Kannalife product offering

Product offering

Core offering

Kannalife Sciences is a biopharmaceutical company focused on the research and development of a pipeline of synthetic CBD-inspired New Chemical Entities (NCEs) targeting neuroinflammation and mitochondrial dysfunction. Its lead drug candidate KLS-13019 is being advanced for chemotherapy-induced peripheral neuropathy (CIPN), Parkinson's disease, opioid use disorder, and hepatic encephalopathy, while Atopidine™ is being prepared as an OTC topical skin care product.

Product overview

Kannalife Sciences is a biopharmaceutical company developing a pipeline of synthetic CBD-like therapeutic molecules. The core portfolio consists of KLS-13019 as the lead drug candidate for multiple indications including CIPN, Parkinson's disease, and opioid use disorder; KLS-13023 as an oral formulation for Hepatic Encephalopathy; and KLS-13022 as a topical cream for skin disorders. Additionally, Atopidine™ represents a consumer-facing topical product for anti-inflammatory skin care applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Atopidine™: A proprietary, investigational, novel monotherapeutic product for potential treatment of skin care, anti-inflammatory, antioxidant, and personal care needs. A CBD-inspired molecule shown to outperform CBD in preventing inflammatory responses relevant to UVB-radiation.

Products and services

  • KLS-13019 First-in-class synthetic CBD-like New Chemical Entity (NCE) and lead drug candidate targeting chemotherapy-induced peripheral neuropathy (CIPN), Parkinson's disease, opioid use disorder, and refractory colon cancer. Features a dual mechanism of action: GPR55 antagonism (anti-inflammatory) and mitochondrial NCX-1 regulation (neuroprotection). Demonstrated 67% oral bioavailability and blood-brain barrier penetration.
  • KLS-13023 Oral gelcap therapeutic candidate in the KLS family designed to target neurotoxicity caused by ammonia and ethanol in the brain for potential treatment of Hepatic Encephalopathy (HE). Shown to be 50x more potent than CBD in protecting hippocampal neurons from oxidative stress associated with liver failure.
  • KLS-13022 Topical cream formulation in early discovery/optimization stage targeting OTC skin disorders including pain, itch, and burn indications, with a target to be OTC ready by late 2026.
  • Atopidine™ (LEA) Proprietary, investigational topical formulation (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine / LEA) intended for skin care and anti-inflammatory consumer applications. Shown in pre-clinical testing to have protective and anti-inflammatory properties, outperforming CBD in preventing inflammatory responses relevant to UVB-radiation including TNF-alpha, IL-1beta and IL-6 release from human epidermal cells. Planned for OTC launch.

Quantifiable outcome

  • KLS-13019 is up to 200X more potent than CBD
  • +6 more outcomes

Companies that use Kannalife

Customer profile

Segments6 records

Ideal customer profiles2 records

Kannalife technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Kannalife partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major, core, strategic and supporting.

  • Universitätsklinikum Würzburg (University of Würzburg)majorStrategic or Co-development Partner · 25 June 2024Research partnership with Prof. Dr. Med. Chi Wang Ip for Parkinson's disease research program. Collaboration as part of MJFF-funded preclinical studies on KLS-13019 targeting neuroinflammation and mitochondrial dysfunction.
  • Atuka, Inc.majorStrategic or Co-development Partner · 25 June 2024Research partnership with Tom H. Johnston, PhD and James P. Koprich, MA, PhD for Parkinson's disease research program. Collaboration on preclinical efficacy studies of KLS-13019 for PD treatment.
  • Lewis Katz School of Medicine at Temple UniversitycoreStrategic or Co-development Partner · 11 February 2020Collaborative research with Dr. Sara Jane Ward's laboratory for KLS-13019 studies in animal models of chemotherapy-induced peripheral neuropathy (CIPN). Research performed under NIH-NIDA Phase 1 grant (1R41DA044898-01) to assess KLS-13019 as non-opioid treatment for neuropathic pain.
  • PurisysstrategicTechnology or IntegrationPartnership for Chemistry, Manufacturing, and Controls (CMC) services. Partners in proprietary, scaled-up CMC for KLS-13019 drug substance and drug product manufacturing for IND-enabling studies and clinical trials.
  • Pennsylvania Biotechnology Center (PABC)supportingOthersNonprofit life sciences incubator-accelerator providing state-of-the-art laboratory and office space to Kannalife. Located near Doylestown in the Philadelphia-New Jersey pharma belt. Supports nearly 80 member companies.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Kannalife competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Major biopharma with historic leadership in neuropathic pain and CIPN therapeutics. Relevant as the archetypal acquirer/partner for late-stage cannabinoid or non-opioid pain assets.
  • Tilray Brands: Large, publicly traded cannabis company with pharmaceutical division pursuing cannabinoid-derived therapeutics. Comparable in cannabinoid therapeutic pipeline but operates at significantly larger scale and broader commercial footprint.
  • Jazz Pharmaceuticals: Acquired GW Pharmaceuticals, the global leader in approved cannabinoid therapeutics (Sativex, Epidiolex), making it the most directly comparable large pharma counterpart in cannabinoid CNS drug development. Competes for the same physician and patient pools that Kannalife's KLS-13019 targets in neuropathic pain and neurology.

Direct peers

  • Axsome Therapeutics: CNS-focused biopharmaceutical company developing therapeutics for migraine, depression, and CNS disorders. Highly relevant non-opioid neuropathic pain and CNS comparator with similar small-cap, R&D-intensive profile.
  • Corbus Pharmaceuticals: Clinical-stage biopharmaceutical company developing cannabinoid-derived and related small molecules for inflammatory and fibrotic diseases. Closely comparable in stage, therapeutic philosophy (synthetic cannabinoid-inspired NCEs), and CNS/inflammation pipeline focus.
  • Tetra Bio-Pharma: Canadian cannabinoid-based drug development company focused on pain, inflammation, and oncology-supportive care. Overlaps with Kannalife on cannabinoid-derived molecules for neuropathic pain and CIPN-like indications.
  • AXIM Biotechnologies: Cannabinoid-focused biotech with overlapping board and investor connections to Kannalife. Pursues cannabinoid therapeutics in pain and CNS indications, making it a closely comparable small-cap peer.
  • InMed Pharmaceuticals: Clinical-stage company developing cannabinoid-based therapeutics for diseases with high unmet medical need. Comparable in being a small-cap, R&D-focused cannabinoid pharma pursuing CNS and rare-disease indications.

Others

Emerging players

  • PureTech Health: Clinical-stage biotherapeutics company developing CNS and inflammation programs. Comparable as a small, R&D-heavy platform developing CNS-focused novel mechanisms toward partnership with larger pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Kannalife social profiles

Digital presence

Kannalife financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kannalife leadership team

Management profile

Number of profiles

Profiles10 records

Kannalife funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kannalife M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kannalife

What does Kannalife do?

Kannalife Sciences is a biopharmaceutical company focused on the research and development of a pipeline of synthetic CBD-inspired New Chemical Entities (NCEs) targeting neuroinflammation and mitochondrial dysfunction. Its lead drug candidate KLS-13019 is being advanced for chemotherapy-induced peripheral neuropathy (CIPN), Parkinson's disease, opioid use disorder, and hepatic encephalopathy, while Atopidine™ is being prepared as an OTC topical skin care product.

Is Kannalife a public or private company?

Kannalife is a public company. It is classified as public and is currently operating.

When was Kannalife founded?

Kannalife was founded in 2010. It employs 1 to 10 people.

Where is Kannalife based?

Kannalife is headquartered in Doylestown, United States, in the North America region.

How does Kannalife make money?

One revenue line is on record: grant Funding.

Who are Kannalife's main competitors?

Broad incumbents on record are Pfizer, Tilray Brands and Jazz Pharmaceuticals. Direct peers are Axsome Therapeutics, Corbus Pharmaceuticals, Tetra Bio-Pharma, AXIM Biotechnologies and InMed Pharmaceuticals. AstraZeneca is listed as an others. PureTech Health is listed as an emerging player.

Does Kannalife have an API?

No public API is recorded for Kannalife.

What industry is Kannalife in?

Kannalife's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAKAIAO, Neurogenetics & Rare Neurologic Diseases. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooMedical Marijuana, Inc. Portfolio Investment Company Neuropathix Announces Grant Award for Parkinson's ResearchMedical Marijuana, Inc. announced that its subsidiary Kannalife Sciences received $1.49 million in grant funding from the Michael J. Fox Foundation for Parkinson's research using its cannabinoid therapeutic KLS-13019. The company owns about 22% of Kannalife's parent Neuropathix, and the funding aims to advance preclinical studies and potential clinical trials.KannalifeKannalife Secures Funding of $1.49 Million from The Michael J. Fox Foundation for Parkinson’s ResearchKannalife Sciences secured a $1.49 million grant from The Michael J. Fox Foundation to fund preclinical research on its therapeutic candidate KLS-13019 for Parkinson’s disease. This funding supports the investigation of the drug's effects on neuroinflammation and mitochondrial dysfunction, building on prior validation from an NIH STTR Phase 2 study.BioSpaceKannalife Secures Funding of $1.49 Million from The Michael J. Fox Foundation for Parkinson’s ResearchKannalife Sciences received a $1.49 million grant from The Michael J. Fox Foundation to fund preclinical research on its lead therapeutic, KLS-13019, for Parkinson's disease. The funding will support studies investigating the drug's effects on neuroinflammation and mitochondrial dysfunction. This grant complements existing National Institutes of Health support for the compound's development.GlobeNewswireKannalife Secures Funding of $1.49 Million from The Michael J. Fox Foundation for Parkinson’s ResearchKannalife Sciences has secured a $1.49 million grant from The Michael J. Fox Foundation to fund preclinical research on its lead therapeutic, KLS-13019, for Parkinson’s disease. This funding will support investigations into the drug's effects on neuroinflammation and mitochondrial dysfunction, building upon previous validation of its biological targets. The grant aims to accelerate the development of novel interventions for Parkinson's and potentially other inflammatory diseases.YahooNeuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)Neuropathix, Inc. announced that its wholly owned subsidiary, Kannalife Sciences, Inc., has been awarded a $2.97 million Phase 2 STTR Study Grant from the National Institute of Neurological Disorders and Stroke (NINDS). The three-year grant is designated for the development of KLS-13019, a non-opioid anti-inflammatory compound intended to treat chemotherapy-induced peripheral neuropathy. The funding will support preclinical studies and preparation for FDA Phase 1 human clinical trials.BioSpaceNeuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)Neuropathix, Inc. announced that its wholly owned subsidiary, Kannalife Sciences, Inc., received a $2.97 million Phase 2 STTR Study Grant from the National Institute of Neurological Disorders and Stroke (NINDS). The funding, provided through the NIH HEAL Initiative, will support preclinical studies for KLS-13019, a non-opioid compound intended to treat chemotherapy-induced peripheral neuropathy. This grant enables the company to prepare for future FDA Phase 1 human clinical trials.GlobeNewswireKannalife, Inc. Rebrands as Neuropathix, Inc. and Unveils New Ticker SymbolKannalife, Inc. changed its name to Neuropathix, Inc. and adopted the new ticker symbol NPTX. The company, a biopharmaceutical medchem firm, will now focus on developing novel monotherapeutics for neurodegenerative disorders, including its leading compound KLS-13019 for chemotherapy-induced peripheral neuropathy.GlobeNewswireKannalife, Inc. Adds to Its Global IP Estate Receiving Patent Grant from Canada for Its Novel Anti-Inflammatory CompoundsKannalife, Inc. received Canadian Patent CA2936506A1 for its novel anti-inflammatory compounds targeting neurodegenerative diseases and neuropathic pain. The patent covers compounds like KLS-13019, which outperformed CBD in preclinical testing for chemotherapy-induced peripheral neuropathy. The company now has seven pharmaceutical jurisdictions, with Brazil and India pending.GlobeNewswireKannalife, Inc. Appoints Dr. Tage Honoré as Chairman of the Company’s Board of AdvisorsKannalife, Inc. appointed Dr. Tage Honoré as Chairman of its Board of Advisors. Dr. Honoré is a pharmaceutical and biotechnology executive with expertise in CNS and PNS diseases, including Alzheimer's and ALS. The appointment aims to support Kannalife's clinical development of KLS-13019 for neurodegenerative disorders.GlobeNewswireKannalife, Inc. Receives Patent Grants in Additional European TerritoriesKannalife, Inc. received patent grants in Austria, Luxembourg, Liechtenstein, and Monaco for its PCT patent on functionalized 1,3-benzene diols for hepatic encephalopathy. The grants bring near global coverage in top pharmaceutical markets, and the company now holds 23 patents worldwide, including two U.S. patents.